Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker BTAIQ
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | Frank Yocca Chief Scientific Officer | BTAI BioXcel Therapeutics, Inc. | Sale | 6,845 | $1.09 | $7,461 Sale | Form 4 ↗ |
| May 20, 2026 | Javier Rodriguez See Remarks | BTAI BioXcel Therapeutics, Inc. | Sale | 6,560 | $1.08 | $7,085 Sale | Form 4 ↗ |
| May 20, 2026 | Richard I. Steinhart Chief Financial Officer | BTAI BioXcel Therapeutics, Inc. | Sale | 6,845 | $1.09 | $7,461 Sale | Form 4 ↗ |
| May 20, 2026 | Vimal Mehta CEO and President, Director | BTAI BioXcel Therapeutics, Inc. | Sale | 19,419 | $1.09 | $21.2K Sale | Form 4 ↗ |
| Dec 16, 2024 | Vincent O'Neill See Remarks | BTAI BioXcel Therapeutics, Inc. | Sale | 165 | $0.35 | $57.75 Sale | Form 4 ↗ |
| Dec 16, 2024 | Vimal Mehta CEO and President, Director, 10% owner | BTAI BioXcel Therapeutics, Inc. | Sale | 2,134 | $0.36 | $768 Sale | Form 4 ↗ |
| Dec 16, 2024 | Vimal Mehta CEO and President, Director, 10% owner | BTAI BioXcel Therapeutics, Inc. | Sale | 983 | $0.36 | $354 Sale | Form 4 ↗ |
| Dec 16, 2024 | Richard I. Steinhart Chief Financial Officer | BTAI BioXcel Therapeutics, Inc. | Sale | 372 | $0.36 | $134 Sale | Form 4 ↗ |
| Dec 16, 2024 | Richard I. Steinhart Chief Financial Officer | BTAI BioXcel Therapeutics, Inc. | Sale | 205 | $0.36 | $73.8 Sale | Form 4 ↗ |
| Dec 16, 2024 | Javier Rodriguez See Remarks | BTAI ] BioXcel Therapeutics, Inc. | Sale | 220 | $0.36 | $79.2 Sale | Form 4 ↗ |
| Dec 16, 2024 | Javier Rodriguez See Remarks | BTAI ] BioXcel Therapeutics, Inc. | Sale | 210 | $0.36 | $75.6 Sale | Form 4 ↗ |
| Dec 16, 2024 | Frank Yocca Chief Scientific Officer | BTAI BioXcel Therapeutics, Inc. | Sale | 225 | $0.35 | $78.75 Sale | Form 4 ↗ |
| Dec 16, 2024 | Frank Yocca Chief Scientific Officer | BTAI BioXcel Therapeutics, Inc. | Sale | 205 | $0.36 | $73.8 Sale | Form 4 ↗ |
| Oct 3, 2024 | Matthew T. Wiley Chief Commercial Officer | BTAI BioXcel Therapeutics, Inc. | Sale | 6,272 | $0.55 | $3,450 Sale | Form 4 ↗ |
| Oct 3, 2024 | Javier Rodriguez See Remarks | BTAI BioXcel Therapeutics, Inc. | Sale | 6,863 | $0.55 | $3,775 Sale | Form 4 ↗ |
| Oct 3, 2024 | Frank Yocca Chief Scientific Officer | BTAI BioXcel Therapeutics, Inc. | Sale | 7,175 | $0.55 | $3,946 Sale | Form 4 ↗ |
| Oct 3, 2024 | Richard I. Steinhart Chief Financial Officer | BTAI BioXcel Therapeutics, Inc. | Sale | 7,175 | $0.55 | $3,946 Sale | Form 4 ↗ |
| Oct 3, 2024 | Vincent O'Neill See Remarks | BTAI BioXcel Therapeutics, Inc. | Sale | 5,556 | $0.55 | $3,056 Sale | Form 4 ↗ |
18 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:24 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances